Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Angiogenic factors alone or in combination with ultrasound Doppler criteria for risk classification among late-onset small fetuses with or without pre-eclampsia.
Ultrasound Obstet Gynecol
January 2025
BCNatal, Barcelona Center for Maternal-Fetal and Neonatal Medicine, Hospital Clínic and Hospital Sant Joan de Déu, IDIBAPS, University of Barcelona, Barcelona, Spain.
Objective: To investigate the prognostic value of maternal angiogenic factors in late-onset small fetuses, alone or in combination with the ultrasound and Doppler parameters currently used for the classification of low-risk small-for-gestational-age (SGA) fetuses or high-risk fetal growth restriction (FGR), overall and according to the presence or absence of pre-eclampsia.
Methods: This was a prospective cohort study of women with a singleton pregnancy with a diagnosis of late-onset fetal smallness (defined as birth weight < 10 centile) and a gestational age of ≥ 34 weeks at delivery. Ultrasound assessment of estimated fetal weight (EFW) and Doppler assessment of uterine artery pulsatility index (UtA-PI) and cerebroplacental ratio (CPR) were performed every 1-2 weeks.
Relationships of maternal hemodynamics in the third trimester with fetal umbilical artery doppler indices, estimated fetal weight and birth weight in women with and without congenital heart disease.
Int J Gynaecol Obstet
January 2025
Imperial College London, Chelsea And Westminster Hospital, London, UK.
Objective: To compare differences in maternal hemodynamics, measured non-invasively by impedance cardiography and mean arterial blood pressure (MAP)-at rest and with high-intensity exercise-between pregnant women with corrected congenital heart disease (CHD) and low-risk (LR) pregnant controls, and to correlate these findings with umbilical artery Doppler in the third trimester, estimated fetal weight (EFW) and birth weight (BW).
Methods: Prospective longitudinal study with hemodynamic exercise studies and fetal ultrasound between 30 and 34 weeks' gestation. Approval was obtained from London South East Research Ethics Committee.
Fresh frozen plasma, fibrinogen concentrate, and antithrombin concentrate administration for obstetrical disseminated intravascular coagulation by the Japanese previous and new criteria.
J Obstet Gynaecol Res
February 2025
Department of Obstetrics and Gynecology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Aim: The purpose of this study is to clarify the frequencies of fresh frozen plasma (FFP) ± fibrinogen concentrate administration (fibrinogen concentrate [FC] therapy) and antithrombin (AT) concentrate administration (AT therapy) for the women with obstetrical disseminated intravascular coagulation (DIC).
Methods: Two retrospective multicenter case-control studies as Study-1 (January-December 2018) and Study-2 (July 2022-June 2023) were conducted. Study-1 was the historical control of Study-2.
A replication study of novel fetal hemoglobin-associated genetic variants in sickle cell disease-only cohorts.
Hum Mol Genet
January 2025
Montreal Heart Institute, 5000 Bélanger Street, Montréal, Québec, H1T 1C8, Canada.
Sickle cell disease (SCD) is the most common monogenic disease in the world and is caused by mutations in the β-globin gene (HBB). Notably, SCD is characterized by extreme clinical heterogeneity. Inter-individual variation in fetal hemoglobin (HbF) levels strongly contributes to this patient-to-patient variability, with high HbF levels associated with decreased morbidity and mortality.
View Article and Find Full Text PDFAstragaloside IV alleviates GDM via regulating gut microbiota and gut microbiota metabolomic.
Front Pharmacol
January 2025
Department of Obstetrics, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China.
Background: Gestational diabetes mellitus (GDM), a severe pregnancy disorder, is a temporary form of diabetes that occurs during gestation. Astragaloside IV (AS IV), a natural and effective composition of , shows pharmacological effects against diabetes. On the contrary, the effects of AS IV on GDM development are still not clear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!